Supplementary Figures for: "Crossancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects on brain"



Summary of all analyses. Top left: Primary analysis for OUD (less stringent) in MVP dataset. Within ancestry GWAS for African American (AA), European American (EA) and Hispanic American (HA) followed by cross-ancestry meta-analysis. These results were used for all downstream analyses. Top right: Supplementary analyses. 1. Within ancestry meta-analysis was conducted for AA between MVP, PGC, YP3 and for EA between MVP, Partners, PGC, YP3, followed by cross-ancestry meta-analysis. 2. Within ancestry OUD (stringent) GWAS for African American (AA), European American (EA) and Hispanic American (HA) followed by cross-ancestry meta-analysis. Bottom: Post GWAS analyses were conducted in Aas, EAs and HAs as indicated.

### Supplementary Figure 2: Within-tissue gene expression (S-PrediXcan)



Within-tissue gene expression conducted using S-PrediXcan. Genes with predicted differential expression in brain-related tissues (left) and non-brain related tissues (right). Color of circle indicates downregulation (red) or upregulation (blue). Size of circle indicates –log10 p-value.

# Supplementary Figure 3: Gene-based analyses



Gene-based Manhattan plots for AA, EA and HA. Gene-based association analyses were conducted using FUMA.

## Supplementary Figure 4: Drug-gene interactions



Drug-gene interactions for 8 genes associated with OUD. The width of the line between each gene and drug class indicates the number of interactions.

- A02 DRUGS FOR ACID RELATED DISORDERS
- A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
- A04 ANTIEMETICS AND ANTINAUSEANTS

#### Supplementary Figure 5: Genetic correlation between OUD and UKBB complex traits



Genetic correlations for OUD in the UK Biobank dataset. All points passing Bonferroni correction are plotted. The color of the circle indicates the phenotypic category. The size of the circle indicates the –log10 p-value.

## Supplementary Figure 6: Mendelian randomization

Intelligence (97)					Intelligence (40)				
IVW	5.18e-01		∔e-i	0.038 (-0.021 to 0.097)	IVW	1.03e-01		) <b></b>	0.037 (0.0
Weighted Median	1.21e-01		i i i i i i i i i i i i i i i i i i i	0.101 (0.036 to 0.166)	Weighted Median	7.06e-01			0.009 (-0.0
MR-Egger	7.65e-01	6.01e-01	i i	-0.057 (-0.248 to 0.134)	MR-Egger	5.95e-01	2.34e-01		-0.034 (-0
Cognitive Performance (417)			1		Cognitive Performance (39)			1	
IVW	2.41e-04	<u></u>		-0.154 (-0.196 to -0.112)	IVW	7.60e-02			-0.035 (-0.
Weighted Median	9.83e-04	1 <del>4</del> 1	1	-0.177 (-0.231 to -0.123)	Weighted Median	8.34e-02		4	-0.025 (-0.
MR-Egger	3.62e-01	8.35e-01	-j	-0.126 (-0.265 to 0.013)	MR-Egger	3.12e-01	6.74e-02	-	0.052 (0.00
Education Attainment (390)			1		Education Attainment (39)				
IVW	1.87e-08	H <b>A</b> H	1	-0.375 (-0.442 to -0.308)	IVW	6.41e-02			-0.026 (-0.
Weighted Median	7.53e-05	Hadra I.	1	-0.331 (-0.415 to -0.247)	Weighted Median	5.03e-02			-0.018 (-0.
MR-Egger	1.91e-02	4.81e-01	1	-0.525 (-0.749 to -0.301)	MR-Egger	3.42e-01	7.68e-02	lei	0.036 (-0.0
Worry Subcluster (218)			1		Worry Subcluster (38)				
IVW	8.49e-07		· · ·	0.407 (0.324 to 0.490)	IVW	9.02e-04			0.053 (0.03
Weighted Median	5.26e-05		. <b>⊢</b> ⊷	0.375 (0.282 to 0.468)	Weighted Median	4.42e-04		<b>A</b>	0.046 (0.03
MR-Egger	2.42e-01	8.37e-01		- 0.348 (0.051 to 0.645)	MR-Egger	3.85e-01	2.09e-02	-	-0.036 (-0.
Depressed Effect Subcluster (21	B)			,	Depressed Effect Subcluster (	38)			
IVW	4.85e-03		1	0.230 (0.148 to 0.312)	IVW	3.69e-03			0.043 (0.02
Weighted Median	1.33e=03		1 LA	0.304 (0.209 to 0.399)	Weighted Median	5.31e-04			0.043 (0.03
MR-Egger	3.23e-01	6.26e-02	4	-0.285 (-0.573 to 0.003)	MR-Egger	6.31e-01	9.226-02	-	-0.019 (-0.
ADHD (55)	51250 01		1	01203 ( 01375 00 01003)	ADHD (38)	01010 01	51220 02	1	0.015 ( 0.
TVW	4.71e=03			0.067 (0.043 to 0.091)	TVW	6.39e=03			0.151 (0.09
Weighted Median	2.490-01		-	0.038 (0.005 to 0.070)	Weighted Median	7.986_03			0.118 (0.09
MR-Egger	9.520-01	3.51e=01	1	0.004 (=0.067 to 0.076)	MR-Enger	7.720-02	3.58e=01		0.296 (0.13
Neuroticism (310)	J.J28-01	5.513-01 ·	1	0.004 (-0.007 10 0.078)	Neuroticiem (38)	/./2e=02	5.500-01		0.250 (0.12
Time (510)	2 44- 06		1	0.206 (0.240 += 0.272)	Neurocrorsm (58)	5 62- 01		1	0.050 (0.00
Weighted Median	5 270 04		,	0.276 (0.107 to 0.276)	Lyn Noighted Modion	3 640 00		- C	0.036 (0.04
MB Eggor	4 00- 01	5 220 01		0.270 (0.197 to 0.356)	Weighted Median	5.04e-02	3 030 03		0.028 (0.01
MDD (192)	4.998-01	5.//d=01 F	· • · ·	0.170 (-0.082 to 0.422)	MDD (26)	4.32e-01	2.020-02		-0.034 (-0.
TINA	1 64- 02		1.4	0 151 (0 102 1 - 0 100)	(30) UUN	6 20			0 102 /0 27
LVW Weighted Medica	1.040-03			0.100 (0.112 to 0.199)	LVW Noighted Wedler	6./8e-04			0.103 (0.07
weighted Median	3./1e=04	F 0F- 01	Hand I have been started at the started starte	0.199 (0.143 to 0.255)	weighted Median	1.68e-04	2 42- 01	-	0.098 (0.07
MK-Egger	1.22e-01	5.056-01		0.258 (0.091 to 0.425)	MK-Egger	8.90e-01	2.430-01		0.012 (-0.0
SCRIZOPhrenia (334)	2 01 12		1.	0 111 /0 000 / 0 101	Schizophrenia (38)	0.00			0.005 .0
IVW	2.91e-18			0.111 (0.098 to 0.124)	IVW	2.90e-04			0.225 (0.16
Weighted Median	1.24e-10		<b>A</b>	0.103 (0.087 to 0.119)	Weighted Median	7.44e-03		HeH	0.142 (0.08
MR-Egger	6.80e-03	7.63e-01	1 101	0.125 (0.079 to 0.171)	MR-Egger	8.51e-01	2.51e-01		0.033 (-0.1
Cross Disorder (351)			1		Cross Disorder (34)			1	
IVW	2.61e-08		1	0.082 (0.067 to 0.096)	IVW	1.57e-06		l 📥	0.304 (0.24
Weighted Median	6.22e-03			0.056 (0.035 to 0.076)	Weighted Median	4.18e-07		H +++	0.386 (0.31
MR-Egger	4.43e-01	3.58e-03 ⊦	•}	-0.032 (-0.073 to 0.010)	MR-Egger	8.77e-02	4.84e-01		0.507 (0.21
Bipolar Disorder (207)			1		Bipolar Disorder (37)				
IVW	2.44e-08		<b>A</b>	0.080 (0.065 to 0.094)	IVW	7.45e-03		H <b>e</b> H	0.144 (0.09
Weighted Median	5.41e-03			0.055 (0.035 to 0.075)	Weighted Median	1.83e-02		нн	0.117 (0.06
MR-Egger	6.58e-01	1.05e-02	μų.	-0.018 (-0.059 to 0.023)	MR-Egger	7.08e-01	6.19e-01		0.064 (-0.1
Number Sexual Partners (219)			1		Number Sexual Partners (40)			1	
IVW	8.49e-04		H <b>A</b> H	0.289 (0.202 to 0.375)	IVW	6.23e-04		A	0.062 (0.04
Weighted Median	1.51e-03		¦ <b>⊢</b> ≜⊣	0.300 (0.205 to 0.395)	Weighted Median	3.25e-03		<b> •</b>	0.039 (0.02
MR-Egger	8.88e-03	6.47e-02	1	▶ 0.915 (0.565 to 1.265)	MR-Egger	4.63e-01	2.66e-02	H.	-0.034 (-0.
General Risk Tolerance (118)					General Risk Tolerance (40)				
IVW	4.79e-02		i 🛏	0.239 (0.118 to 0.360)	IVW	1.57e-03		*	0.030 (0.02
Weighted Median	4.35e-01		Ļ.	0.117 (-0.033 to 0.267)	Weighted Median	1.13e-03		<b>▲</b>	0.032 (0.02
MR-Egger	6.34e-01	9.30e-01	· •	→ 0.203 (-0.223 to 0.629)	MR-Egger	9.12e-01	2.55e-01	÷	0.003 (-0.0
Insomnia (93)			1		Insomnia (38)				
IVW	2.08e-01		) <del>I</del> III	0.064 (0.013 to 0.115)	IVW	1.61e-01		)e	0.032 (0.00
Weighted Median	2.22e-01		hee .	0.081 (0.015 to 0.148)	Weighted Median	1.08e-01		-	0.040 (0.01
MR-Egger	6.83e-01	9.69e-01 ⊢	•	0.071 (-0.102 to 0.244)	MR-Egger	8.51e-01	4.54e-01		-0.012 (-0.
Smoke Cessation (33)					Smoke Cessation (40)				
IVW	9.88e-01	F	÷	0.002 (-0.120 to 0.124)	IVW	4.85e-01			0.016 (-0.0
Weighted Median	6.23e-01	-	Ļ.	-0.059 (-0.180 to 0.062)	Weighted Median	7.04e-01		÷	0.009 (-0.0
MR-Egger	4.97e-01	4.67e-01	÷	-0.244 (-0.604 to 0.116)	MR-Egger	3.12e-01	4.18e-01	<b> </b> ••	0.062 (0.00
Age of Initiation (47)			1		Age of Initiation (40)				
IVW	2.59e-02		1	-0.282 (-0.409 to -0.155)	IVW	1.59e-01		4	-0.016 (-0.
Weighted Median	3.98e-02		1	-0.355 (-0.527 to -0.183)	Weighted Median	5.57e-03		•	-0.036 (-0.
MR-Egger	7.69e-01	7.32e-01	<u>.                                    </u>	-0.133 (-0.586 to 0.320)	MR-Egger	4.69e-01	1.76e-01	i iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	0.021 (-0.0
NO2A: Opioids (45)			1		NO2A: Opioids (35)				
IVW	2.59e-02			-0.282 (-0.409 to -0.155)	IVW	6.76e-03		101	0.126 (0.08
Weighted Median	3.98e-02		1	-0.355 (-0.527 to -0.183)	Weighted Median	1.91e-01		Her .	0.068 (0.01
MR-Egger	7.69e-01	7.32e-01	<u> </u>	-0.133 (-0.586 to 0.320)	MR-Egger	1.61e-01	5.73e-01		0.203 (0.05
Drinks Per Week (122)					Drinks Per Week (40)				
IVW	9.880-08		1	0.716 (0.582 to 0.850)	IVW	6.320-06			0.048 (0.03
Weighted Median	1.83e-07		1	0.822 (0.664 to 0.980)	Weighted Median	3.30e=06		- <b>A</b>	0.046 (0.03
MR-Egger	1.49e-01	6.66e-01	·	0.559 (0.172 to 0.946)	MR-Egger	5,19e=02	7.54e-01	le la	0.056 (0.02
Cigarettes Per Day (75)	11156-01		1		Cigarettes Per Day (40)	0.190-02		1	
TWW	8.530-04		1	0.153 (0.107 to 0.199)	TVW	9.590-01		1	0.001 (-0.0
Weighted Modian	1 550 02			0.187 (0.129 to 0.246)	Weighted Modian	4 200 01		1	-0.020 (-0.0
MB Eggor	2 12- 01	4 800 01		0.104 (0.020 to 0.240)	WE Page	4.298-01	6 830 01	-	-0.020 (-0.
mm-rgger	2.130-01	4.900-01		0.104 (0.020 to 0.188)	mx-syyer	0.99e-01	0.938-01		0.024 (-0.0
FIODIEMATIC AICHOI USE (151)	2 04- 16			705 /0 600 +	PAU (40)	2 04- 12			0.104 (0.00
TAM	3.04e-16			→ 0./95 (0.698 to 0.892)	TAM	2.94e-13			0.104 (0.09
Weighted Median	8.46e-15	4 00- 00		0.823 (0./17 to 0.929)	Weighted Median	2.30e-13	1 01- 01	<b>A</b>	0.107 (0.09
MR-Egger	5.84e-01	4.890-02 H	· · · ·	0.1/9 (-0.148 to 0.506)	MR-Egger	1.83e-01	1.910-01	jei I	0.054 (0.01
Cannbis Use Disorder (30)			1		Cannabis Use Disorder (40)				
IVW	8.45e-03		1.00	0.080 (0.049 to 0.110)	IVW	1.24e-06		i i i i i i i i i i i i i i i i i i i	0.296 (0.23
	6 490 02		1101	0.067 (0.031 to 0.103)	Weighted Median	1.13e-04		1 H <b>A</b> H	0.302 (0.22
weighted Median	0.496-02								

Causal association for traits genetically correlated with OUD. Left: Traits as the exposure, OUD as the outcome. Right: OUD as the exposure, traits as the outcome. Estimates and p-values for each MR analysis [Inverse variance weighted (IVW), Weighted median, and MR-Egger] are shown. Intercept p-value: MR-Egger horizontal pleiotropy test.

Supplementary Figure 7: PheWAS in Yale-Penn AA individuals



PheWAS plot for OUD PRS in AA individuals from Yale-Penn. No phenotypes pass Bonferroni correction.

Supplementary Figure 8: PheWAS in BioVU AA individuals



PheWAS plot for OUD PRS in AA individuals from BioVU. No phenotypes pass Bonferroni correction.